Research

With its innovative Clinical Trials Network, influential annual meeting and high-impact journals, SNMMI encourages and facilitates research and science for the nuclear medicine and molecular imaging field. Learn more.

Clinical Trials Network

The Clinical Trials Network (CTN) provides tools and resources to promote faster, more cost-effective drug development and increase the availability and performance of molecular imaging radiopharmaceuticals for use in the clinic. Our Mission is to advance the use of molecular imaging agents in clinical trials through standardization of chemistry and imaging methodology. This includes using imaging radiopharmaceuticals during the course of drug development, as well as bringing new radiopharmaceuticals to regulatory approval. Programs developed over the past 5 years include a comprehensive registry of qualified imaging sites and radiopharmaceutical manufacturers, a robust scanner validation program, access to standardized imaging protocols and a very strong clinical research education curriculum.

LATEST NEWS

  • September 14, 2017New Book Available on Abdominal Imaging
    "Abdominal Imaging 2017: Quality, Safety, & Dose Optimization" is the second installment in a series of books dedicated to a single nuclear medicine procedure or imaging category. The book is put out by the SNMMI-TS Publications Committee, and chapters cover imaging rationale, indications, contraindications, patient preparation and education, imaging procedure, processing, interpretation including normal and abnormal results, sensitivity/specificity/accuracy, and artifacts.
  • September 13, 2017Theranostics: Paintball Targeting of Cancer Cells Combined with Precision Therapy
    The Journal of Nuclear Medicine’s September supplement shines a spotlight on theranostics and its increasingly important role in delivering precision medicine. Theranostics refers to the combination of a predictive biomarker, identified through diagnostic imaging using radiolabeled ligands, with precise therapy targeted on the now-marked cancer cells. The cancer cells are destroyed, while healthy cells are unharmed.
  • September 7, 2017Double Targeting Ligands to Identify and Treat Prostate Cancer
    Researchers have demonstrated a new, effective way to precisely identify and localize prostate cancer tumors while protecting healthy tissue and reducing side effects. The study is presented in the featured basic article of the September issue of The Journal of Nuclear Medicine.
  • September 5, 2017FDG-PET/CT Predicts Melanoma Patients’ Response to Immune Checkpoint Inhibitor Therapy
    Research highlighted in the featured article of the September issue of The Journal of Nuclear Medicine demonstrates that combined PET/CT scanning early in the treatment of advanced melanoma could identify whether immune checkpoint inhibitor therapy will benefit a particular patient. As the therapy has potentially serious side-effects, early determination of ineffectiveness could avert unnecessary risk exposure and provide the option of a different treatment.
  • August 18, 2017Joint document details how to diagnose, treat cardiac sarcoidosis
    The American Society of Nuclear Cardiology (ASNC) and the Society of Nuclear Medicine and Molecular Imaging (SNMMI) have issued a joint consensus document on the role of F-18-FDG PET/CT in the diagnosis and treatment of cardiac sarcoidosis.
  • August 10, 2017First Human Application of Novel PET Tracer for Prostate Cancer
    In the featured translational article in the August issue of The Journal of Nuclear Medicine, researchers at the University of Michigan demonstrate the potential of a new PET tracer, Carbon-11 labeled sarcosine, for imaging prostate cancer, and set the stage for its possible use in monitoring other cancers.
  • August 10, 2017First Human Application of Novel PET Tracer for Prostate Cancer
    In the featured translational article in the August issue of The Journal of Nuclear Medicine, researchers at the University of Michigan demonstrate the potential of a new PET tracer, Carbon-11 labeled sarcosine, for imaging prostate cancer, and set the stage for its possible use in monitoring other cancers.
  • August 7, 2017First Human Application of Novel PET Tracer for Prostate Cancer
    In the featured translational article in the August issue of The Journal of Nuclear Medicine, researchers at the University of Michigan demonstrate the potential of a new PET tracer, Carbon-11 labeled sarcosine (11C-sarcosine), for imaging prostate cancer, and set the stage for its possible use in monitoring other cancers.

Preclinical Imaging

CMIIT’s mission is to engage the molecular imaging community and leverage the SNMMI infrastructure to advance the adoption of emerging molecular imaging technologies and probes in preclinical and clinical applications. One of the goals is to develop educational resources for a “translational researcher”. CMIIT will provide researchers with needed education and training on the “nuts and bolts” of translating and transitioning an agent or technique from pre-clinical research into the clinical practice such as tracer development, equipment, and funding.

The Nuclear Medicine Clinical Trial Group, LLC

Under the auspices of the Society of Nuclear Medicine and Molecular Imaging, the Nuclear Medicine Clinical Trial Group(NMCTG) assists industry partners and academic investigators in managing clinical research activities.  Its goals include ensuring quality imaging is conducted in drug or diagnostic clinical trials and providing training for molecular imaging professionals performing clinical research. Many of the programs established under the Clinical Trials Network, such as its robust Education Program, provide support to the NMCTG to help carry out its mission.